Becton, Dickinson and Company (BDX) has globally launched its latest glass prefillable syringe system, the BD Neopak. The advanced device is used for biopharmaceutical injectable drug delivery.
The BD Neopak Glass Prefillable Syringe provides high quality container and device integration support, which in turn allows its pharmaceutical customers to safely deliver drugs to patients. The fully indexed lines on the syringe with no possibility of glass-to-glass contact limit visual defects and strengthens the quality of the glass. The new process also reduces silicone quantity.
The unique design of the prefillable syringe system helps to optimize filling of biologic drugs, among the top selling drugs in the world. The BD XSi cross-linked silicone technology and the ultralow tungsten technology in the BD Neopak, further aids BD’s pharmaceutical clients to market sensitive drugs.
BDX will provide additional services such as customized drug compatibility assessments, functional requirements (drug and system related) as well as registration and post-launch help to aid drug development with the BD Neopak.
The worldwide commercial launch of this new offering should boost the company’s Pharmaceutical System division’s revenues under the BD Medical segment. In the last reported quarter, sales of this franchise were up 3.0% (up 2.4% in constant currency) to $291.4 million.
The stock currently carries a Zacks Rank #2 (Buy). We remain encouraged by the company’s solid fiscal second-quarter results, which exceeded expectations. Moreover, the upward revision in guidance for the ongoing fiscal reflects positive drivers.
Becton Dickinson’s preeminent global healthcare products franchise is partly insulated from volatile macroeconomic conditions and structural deficiencies elsewhere in the healthcare delivery field.
Other medical stocks that warrant a look include CONMED (CNMD), The Cooper Companies (COO) and West Pharmaceutical Services (WST). All the stocks carry a Zacks Rank #2 (Buy).
More From Zacks.com